BIIB021_848695-25-0_CoA_MedChemExpress
MedBio_CAS号210830-32-3 N-Me-D-Val-OH·HCl相关物理参数
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11116
Fmoc-(2-氯苄氧基羰基)赖氨酸
Fmoc-Lys(2-Cl-Z)-OH
133970-31-7
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11078
Fmoc-N-甲基-D-亮氨酸
Fmoc-D-N-Me-Leu-OH
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11079
N-叔丁氧羰基-N-甲基-D-苯丙氨酸二环己胺盐
Boc-D-N-Me-Phe.DCHA
102185-45-5
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11002
2-(叔-丁氧基碳酰胺)-2-苯乙腈
Boc-ON
58632-95-4
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11120
N,N'-双芴甲氧羰基-L-赖氨酸
Fmoc-Lys(Fmoc)-OH
78081-87-5
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11110
Fmoc-L-异亮氨酸
Fmoc-Ile-OH
BIIB021_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :BIIB021Catalog No. :HY-10212CAS No. :848695-25-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:CNF2024; BIIB⁻021; BIIB 021; CNF 2024; CNF⁻2024Formula:C14H15ClN6OMolecular Weight:318.76CAS No. :848695-25-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 2Additional informationExposure may cause irritation to eyes, mucous membranes, upper respiratory tract and skinThis information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.12. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling orfrom contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
阿替卡因肾上腺素注射液在牙体牙髓病治疗中的临床效果分析
药物与临床China &Foreign Medical Treatment 中外医疗阿替卡因肾上腺素注射液在牙体牙髓病治疗中的临床效果分析刘志省，魏宾，马贵廷滕州市中医医院口腔科，山东滕州 277599［摘要］ 目的 针对罹患牙体牙髓病患者，探究在其临床治疗中给予阿替卡因肾上腺素注射液所得疗效。
方法 随机选取2019年5月—2022年5月滕州市中医医院收治的牙体牙髓病患者100例为研究对象，随机分为两组，每组50例。
对照组运用利多卡因+肾上腺素展开麻醉，观察组运用阿替卡因肾上腺素注射液展开麻醉，比较两组的麻醉起效时间、麻醉持续时间、麻醉总有效率、患者满意度、不良反应发生率。
结果 观察组麻醉起效时间短于对照组，麻醉持续时间长于对照组，差异有统计学意义（χ2=16.107、4.923，P <0.05）。
观察组麻醉总有效率（98.00%）高于对照组（70.00%），差异有统计学意义（χ2=14.583，P <0.05）。
观察组满意度为96.00%，高于对照组的68.00%，差异有统计学意义（χ2=13.279，P <0.05）。
观察组不良反应发生率为6.00%，低于对照组的20.00%，差异有统计学意义（χ2=4.332，P <0.05）。
结论 在牙体牙髓病患者展开治疗时，运用阿替卡因肾上腺素注射液，可明显缩短麻醉起效时间，延长麻醉持续时间，提升患者满意度，降低不良反应发生率。
［关键词］ 阿替卡因肾上腺素注射液；牙体牙髓病；麻醉持续时间；不良反应［中图分类号］ R246.83 ［文献标识码］ A ［文章编号］ 1674-0742（2023）06(a)-0089-05Clinical Effect Analysis of Articaine Epinephrine Injection in the Treat⁃ment of EndodonticsLIU Zhisheng, WEI Bin, MA GuitingDepartment of Stomatology, Tengzhou Hospital of Traditional Chinese Medicine, Tengzhou, Shandong Province, 277599 China[Abstract] Objective To explore the curative effect of articaine epinephrine injection in the clinical treatment of pa⁃tients suffering from endodontic diseases. Methods A total of 100 patients with endodontic disease treated in Teng⁃zhou Hospital of Traditional Chinese Medicine from May 2019 to May 2022 were randomly selected as the study ob⁃jects and randomly divided into two groups with 50 patients in each group. The control group was anesthetized with li⁃docaine and epinephrine, and the observation group was anesthetized with atocaine and epinephrine injection. The ef⁃fective time of anesthesia, duration of anesthesia, total effective rate of anesthesia, patient satisfaction and incidence of adverse reactions were compared between the two groups. Results The onset time of anesthesia in the observation group was shorter than that in the control group, and the duration of anesthesia was longer, and the difference was sta⁃tistically significant (χ2=16.107, 4.923, P <0.05). The total effective rate of anesthesia of the observation group (98.00%) was higher than that of the control group (70.00%), and the difference was statistically significant (χ2=14.583, P <0.05). The satisfaction rate of observation group (96.00%) was higher than that of control group (68.00%), and the difference was statistically significant (χ2=13.279, P <0.05). The incidence of adverse reactions in the observa⁃tion group (6.00%) was lower than that in the control group (20.00%), and the difference was statistically significant(χ2=4.332, P <0.05).Conclusion In the treatment of endodontic patients, the use of atocaine epinephrine injection cansignificantly shorten the onset time of anesthesia, extend the duration of anesthesia, improve patient satisfaction, and DOI ：10.16662/ki.1674-0742.2023.16.089[作者简介] 刘志省（1980-），男，本科，主治医师，研究方向为口腔医学。
重组贻贝粘蛋白的表征及功效评价
生物技术进展 2023 年 第 13 卷 第 4 期 596 ~ 603Current Biotechnology ISSN 2095‑2341研究论文Articles重组贻贝粘蛋白的表征及功效评价李敏 ， 魏文培 ， 乔莎 ， 郝东 ， 周浩 ， 赵硕文 ， 张立峰 ， 侯增淼 *西安德诺海思医疗科技有限公司，西安 710000摘要：为了推进重组贻贝粘蛋白在医疗、化妆品领域的应用，对大肠杆菌规模化发酵及纯化生产获得的重组贻贝粘蛋白进行了表征及功效评价。
经Edman 降解法、基质辅助激光解吸电离飞行时间质谱、PITC 法、非还原型SDS -聚丙烯酰胺凝胶电泳法、凝胶法、改良的Arnow 法对重组贻贝粘蛋白进行氨基酸N 端测序、相对分子量分析、氨基酸组成分析、蛋白纯度分析、内毒素含量测定、多巴含量测定；通过细胞迁移、斑马鱼尾鳍修复效果对重组贻贝粘蛋白进行功效评价。
结果显示，获得的重组贻贝粘蛋白与理论的一级结构一致，蛋白纯度达95%以上，内毒素<10 EU ·mg -1,多巴含量大于5%；重组贻贝粘蛋白浓度为60 μg ·mL -1时能够显著促进细胞增殖的活性（P <0.01）；斑马鱼尾鳍面积样品组与模型对照组相比极显著增加（P <0.001）。
研究结果表明，重组贻贝粘蛋白具有显著的促细胞迁移和修复愈合的功效，具备作为生物医学材料的潜质。
关键词：贻贝粘蛋白；基因重组；生物材料；表征；功效评价DOI ：10.19586/j.20952341.2023.0021 中图分类号：S985.3+1 文献标志码：ACharacterization and Efficacy Evaluation of Recombinant Mussel Adhesive ProteinLI Min ， WEI Wenpei ， QIAO Sha ， HAO Dong ， ZHOU Hao ， ZHAO Shuowen ， ZHANG Lifeng ，HOU Zengmiao *Xi'an DeNovo Hith Medical Technology Co.， Ltd ， Xi'an 710000， ChinaAbstract ：In order to promote the application of recombinant mussel adhesive protein in the medical and cosmetics field ， the recombi⁃nant mussel adhesive protein obtained from scale fermentation and purification of Escherichia coli was characterized and its efficacy was evaluated. Amino acid N -terminal sequencing ， relative molecular weight analysis ， amino acid composition analysis ， protein purityanalysis ， endotoxin content ， dihydroxyphenylalanine （DOPA ） content of recombinant mussel adhesive protein were determined by the following methods ： Edman degradation ， matrix -assisted laser desorption ionization time -of -flight mass spectrometry （MALDI -TOF -MS ）， phenyl -isothiocyanate （PITC ）， nonreductive SDS -polyacrylamide gel electrophoresis （SDS -PAGE ）， gel method ， modified Ar⁃now. The efficacy of recombinant mussel adhesive protein was evaluated by cell migration and repairing effect of zebrafish tail fin. Re⁃sults showed that the obtained recombinant mussel adhesive protein was confirmed to be consistent with the theoretical primary structure ， protein purity of more than 95%， endotoxin <10 EU ·mg -1， DOPA content above 5%. When the recombinant mussel adhesive protein concentration was 60 μg ·mL -1， the effect of promoting cell proliferation was the most obvious ， and it had very significant activity （P <0.01）. The caudal fin area of zebrafish in sample group was significantly increased compared with model control group （P <0.001）. The results indicated that recombinant mussel adhesive protein can promote cell migration and repair healing and has the potential to be used as biomedical materials.Key words ：mussel adhesive protein ； gene recombination ； biological materials ； representation ； efficacy evaluation贻贝粘蛋白（mussel adhesive protein ， MAP ）也称作贻贝足丝蛋白（mussel foot protein ，Mfps ），收稿日期：2023⁃02⁃24； 接受日期：2023⁃03⁃31联系方式：李敏 E -mail:*******************;*通信作者 侯增淼 E -mail:***********************.cn李敏，等：重组贻贝粘蛋白的表征及功效评价是海洋贝类——紫贻贝（Mytilus galloprovincalis）、厚壳贻贝（Mytilus coruscus）、翡翠贻贝（Perna viri⁃dis）等分泌的一种特殊的蛋白质，贻贝中含有多种贻贝粘蛋白，包括贻贝粘蛋白（Mfp 1～6）、前胶原蛋白（precollagens）和基质蛋白（matrix proteins）等［1］。
本刊参考文献著录格式
364中国艾滋病性病2021年4月第27卷第4期Chin J AIDS STD Vo丨.27 No.4 Apr 2021[5] ANGLIN MD, BURKE C, PERROCHET B, et al. History ofthe methamphetamine problem[j], J Psychoactive Drugs,2000,32(2)：137-141.[6] CHENG T, JOHNSTON C, KERR T, et al. Substance usepatterns and unprotected sex among street-involved youth in aCanadian setting：a prospective cohort study ^J. BMC PublicHealth,2016(16)：4.[7] BAILEY SL, GAO W, CLARK DB. Diary study of substanceuse and unsafe sex among adolescents with substance usedisorders[ J]. J Adolesc Health,2006,38( 3) ：213-297.[8] DUNN M, DAY C, BRUNO R, et al. Sexual and injecting riskbehaviours among regular ecstasy users [J]. Addict Behav, 2010,35(2)：157-160.[9] ZUCKERMAN MD, BOYER EW. HIV and club drugs inemerging adulthood [J]. Curr Opin Pediatr, 2012, 24 (2)：219-224.[10]郭巍，曲书泉，丁正伟，等.中国1995 — 2009年吸毒者艾滋病毒感染和梅毒流行趋势分析[J].中华流行病学杂志，2010,31(6)：666-669.[11] BAO YP, LIU ZM. Systematic review of HIV and HCVinfection among drug users in China[j]. Int J STD AIDS,2009,20(6)： 399-405.[12]葛琳，李东民，李培龙，等.2010-2015年中国艾滋病哨点监测人群HIV、梅毒和HCV感染状况分析[J].疾病监测，2017,32(2)：111-117.[13]许艳，王璐.国内外M0岁年龄组人群艾滋病流行特征及危险因素[J].中华流行病学杂志，2011,32(11): 1166-1169.[14] ZHUANG X, LIANG Y, CHOW EP, et al. HIV and HCVprevalence among entrants to methadone maintenance treatmentclinics in China：a systematic review and meta-analysis LJ]-BMC Infect Dis,2012( 12) ： 130.[15] BAO Y, LARNEY S, PEACOCK A, et al. Prevalence of HIV,HCV and HBV infection and sociodemographic characteristicsof people who inject drugs in China：A systematic review andmeta-analysis[j]. Int J Drug Policy,2019( 70)：87-93.L16] WANG BX, ZHANG L, WANG YJ, et al. Epidemiology of syphilis infection among drug users at methadone maintenancetreatment clinics in China：systematic review and meta-analysis[J]. Int J STD AIDS,2014,25(8) ：550-558.[17] ZHANG L, CHOW EP, JING J, et al. HIV prevalence inChina：integration of surveillance data and a systematic review[J ]. Lancet Infect Dis, 2013,13 (11) ： 955-963.[18] BAO YP, LIU ZM, LU L. Review of HIV and HCV infectionamong drug users in China [j]. Current opinion in psychiatry2010,23(3)：187-194.[19] ZHANG L, ZHANG D, CHEN W, et al. High prevalence ofHIV, HCV and tuberculosis and associated risk behavioursamong new entrants of methadone maintenance treatment clinicsin Guangdong Province, China[j]. PLoS One, 2013,8( 10) ：e76931. [20] LUO W, WU Z, POUNDSTONE K, et al. Needle and syringeexchange programmes and prevalence of HIV infection amongintravenous drug users in China [ J ]. Addiction ,2015,110 (Suppll)：61-67.[21 ]陈雯，凌莉，何群，等.广东省社区美沙酮维持治疗项目绩效评价与政策建议[J].中国卫生政策研究，2010,3(3) :39-44.[22] WANG L, GUO W, LI D, et al. HIV epidemic among drugusers in China：1995-2011 [J]. Addiction (Abingdon,England), 2015,110 Suppl l(l)：20-28.[23]樊盼英，汪宁.新型毒品滥用对艾滋病流行的影响[J].中华流行病学杂志，2010，31 (3): 340-343.[24]葛琳，崔岩，王璐，等.2012年全国艾滋病哨点吸毒人群血清学和性行为特征分析[J].中华流行病学杂志，2014, 35 (2):121-123.[25] KOESTERS SC, ROGERS PD, RAJASINGHAM CR. MDMA('ecstasy') and other 'club drugs'. The new epidemic [J]. PediatrClin North Am, 2002,49( 2) ： 415-433.1言息本刊参考文献著录格式凡文内引用他人的结果或结论，均应标注并在文末列出参考文献，只限亲自阅读的近期公开发表过的，未公开发表的文献不列入。
抗过敏药物盐酸松齐拉敏的合成
Chenmical Intermediate当代化工研究138生物制药与研究2017·03抗过敏药物盐酸松齐拉敏的合成＊王碧玉（泉州师范学院 化工与材料学院 福建 362000）摘要：抗过敏药物是医院日常医疗过程中比较常用的一种药物，对患者病情的康复有着重大作用，不仅是医院，就连小的诊所和药店里面也广泛应用到了抗过敏药物。
抗过敏药物的种类繁多，不同的抗敏药物其抗敏效果不一样，有时为了更好的治疗疾病，减轻患者的病痛，医院会利用多种药物合成更有利于患者治疗的新型抗过敏药物，盐酸松齐拉敏就是一种常见的合成抗过敏药物，合成的原料包括2-氨基嘧啶、对甲氧基氯苄和N，N-二甲基-2-氯乙胺，其合成步骤为两次N-烃基化反应，其合成后的总收率为79.2%，最终合成功的结构要通过1H NMR，13C NMR和HR-MS(ESI)确证。
关键词：2-氨基嘧啶；对甲氧基氯苄；N，N-二甲基-2-氯乙胺中图分类号：T 文献标识码：ASynthesis of Anti-allergic Medicine Hydrochloric Acid ThonzylamineWang Biyu（Chemical Engineering and Material College, Quanzhou Normal University, Fujian, 362000）Abstract ：Anti-allergic medicine is the common used medicine in hospitals’ daily medical process and has important function on the recovery ofpatients,besides,it not only has application in hospitals, but also in small clinics and pharmacies. The drug categories are of a great variety and the anti-allergic effect of different anti-allergic medicines is different, sometimes,in order to better treat the isease and release patients’ pain, the hospital will use many kinds of medicines to make new-type anti-allergic synthetic medicine that is more helpful to patients.Hydrochloric acid is one common seen synthetic anti-allergic medicine and its synthetic materials include 2-aminopyrimidine ，methoxybenzyl chloride and N,N-dimethyl-2-chloroethylamine, besides,its synthetic step is two-time N-alkylation, which total recovery rate after synthesis is 79.2%, finally, the structure of synthetic work needs to be confirmed by 1HNMR ，13C NMR and HR-MS(ESI).Key words ：2-aminopyrimidine ；methoxybenzyl chloride ；N,N-dimethyl-2-chloroethylamine据相关研究资料显示，抗过敏要求盐酸松齐拉敏的合成方法一共有两种，一种就是以2-氯嘧啶、对甲氧基氯苄[N'-(4-甲氧基苄基)]和N，N-二甲基乙二胺为原料，经过两次N-烃基化反应合成的方法，另一种则是以4，6-二氯-N-［(4-甲氧基苄基) 甲基］嘧啶-2-胺为原料的合成方法，其中第一种合成方法的总收率为70%～90%，而第二种的为45%～70%。
德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨
DOI：10.16658/ki.1672-4062.2023.17.098德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性探讨林生，谢平，陈予福州市长乐区人民医院内分泌科，福建福州350200[摘要]目的研究德谷门冬双胰岛素注射液治疗2型糖尿病的临床效果及安全性。
方法选取于2022年7月—2023年4月福州市长乐区人民医院收治的2型糖尿病患者98例为研究对象，采用随机抓阄法分为两组，每组49例。
两组均联用常规降糖药物治疗，对照组采用甘精胰岛素注射液治疗，观察组采用德谷门冬双胰岛素注射液治疗。
对比两组临床治疗效果、临床症状好转时间和胰岛素用量情况、糖代谢指标、胰岛素功能指标、不良反应发生情况、心血管不良事件发生情况。
结果观察组总有效率高于对照组，差异有统计学意义（P<0.05）。
观察组尿酮体转阴时间、血糖达标时间、胰岛素用量均优于对照组，差异有统计学意义（P< 0.05）。
观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组，差异有统计学意义（P<0.05）。
观察组胰岛β细胞功能指数高于对照组，胰岛素抵抗指数、空腹胰岛素低于对照组，差异有统计学意义（P<0.05）。
两组恶心呕吐、倦怠乏力、低血糖总发生率比较，差异无统计学意义（P>0.05）。
两组心绞痛、心力衰竭总发生率比较，差异无统计学意义（P>0.05）。
结论德谷门冬双胰岛素注射液治疗2型糖尿病临床效果显著优于甘精胰岛素注射液，但是治疗安全性无显著变化。
[关键词] 2型糖尿病；德谷门冬双胰岛素注射液；不良反应；心血管不良事件[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）09（a）-0098-04Discussion on the Clinical Effect and Safety of Insulin Degludec and Insu⁃lin Aspart Injection in the Treatment of Type 2 Diabetes MellitusLIN Sheng, XIE Ping, CHEN YuDepartment of Endocrinology, Changle District People's Hospital, Fuzhou, Fujian Province, 350200 China[Abstract] Objective To study the clinical effect and safety of insulin degludec and insulin aspart injection in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes admitted to Fuzhou Changle District People's Hospital from July 2022 to April 2023 were selected as the study objects and divided into two groups with 49 cases in each group by random lottery method. Both groups were treated with conventional hypoglycemic drugs, the control group was treated with insulin glargine injection, and the observation group was treated with Degu asparton double insulin injection. The clinical therapeutic effect, time of improvement of clinical symptoms, insulin dosage, glucose metabolism index, insulin function index, occurrence of adverse reactions and cardiovascular adverse events were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The time of urine ketone body turning negative, blood glucose reaching standard and insulin dosage in observation group were better than those in control group, and the differences were statistically significant (P<0.05). Fasting plasma glucose, 2-hour postprandial blood glucose and glycated hemoglobin in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The function index of islet β cells in observation group was higher than that in control group, the insulin resistance index and fasting insulin was lower than that in control group, the dif⁃ference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of [作者简介]林生（1981-），男，本科，副主任医师，研究方向为糖尿病及其并发症的相关临床研究。
乙酰胆碱酯酶抑制剂
上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。
在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。
这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。
但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。
关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。
吡唑衍生物合成、生物活性及罗丹明B类pH荧光探针
吡唑衍生物合成、生物活性及罗丹明B类pH荧光探针一、本文概述本文旨在全面探讨吡唑衍生物的合成方法、生物活性及其在化学和生物领域的应用。
本文还将深入研究罗丹明B类pH荧光探针的性质和应用，以期在分子探针设计和生物检测方面提供新的思路和方法。
我们将详细介绍吡唑衍生物的合成策略，包括原料选择、反应条件优化以及产物分离和纯化等步骤。
通过对合成路线的系统研究，我们期望发现更加高效、环保的合成方法，为吡唑衍生物的大规模生产和应用奠定基础。
我们将对吡唑衍生物的生物活性进行深入研究。
通过体外和体内实验，评估吡唑衍生物在抗菌、抗病毒、抗肿瘤等方面的生物活性，揭示其作用机制和潜在的药用价值。
这些研究不仅有助于拓宽吡唑衍生物的应用领域，还为药物研发和生物治疗提供新的候选分子。
本文还将对罗丹明B类pH荧光探针进行详细阐述。
我们将从探针的设计原理、合成方法、光谱性质、pH响应特性等方面展开研究，以期发现具有高灵敏度、高选择性和快速响应的pH荧光探针。
这些探针在生物检测、环境监测和药物研发等领域具有广泛的应用前景。
本文旨在全面研究吡唑衍生物的合成、生物活性及其在化学和生物领域的应用，同时深入探讨罗丹明B类pH荧光探针的性质和应用。
我们期望通过本文的研究，为相关领域的发展提供新的思路和方法，推动化学和生物科学的进步。
二、吡唑衍生物的合成吡唑衍生物是一类具有广泛生物活性的化合物，其合成方法多种多样，主要包括直接合成法、重排反应法以及多组分反应法等。
直接合成法通常是通过羧酸与肼或酰肼在加热条件下发生缩合反应来制备吡唑衍生物。
这种方法简单易行，是实验室中最常用的合成方法之一。
在反应过程中，需要选择合适的溶剂和温度，以确保反应的顺利进行。
重排反应法则是通过某些特定结构的化合物在加热或催化剂的作用下发生分子内重排反应，从而得到吡唑衍生物。
这种方法通常需要较高的温度和较长的反应时间，但对于某些特定结构的吡唑衍生物合成具有独特的优势。
多组分反应法是一种高效、快速的合成方法，它可以在一步反应中同时形成多个化学键，从而得到目标产物。
赛沃替尼化学结构
赛沃替尼化学结构
赛沃替尼是一种化学药物，其化学名称为1-[(1S)-1-(咪唑并[1,2-a]吡啶-6-基)乙基]-6-(1-甲基-1H-吡唑-4-基)-1H-[1,2,3]三唑并[4,5-b]吡嗪，分子式为C17H15N9，分子量为345.36。
赛沃替尼的化学结构十分独特，它包含了一个咪唑并[1,2-a]吡啶-6-基团，一个1-甲基-1H-吡唑-4-基团，以及一个1H-[1,2,3]三唑并[4,5-b]吡嗪基团。
这些基团通过碳碳键和氮氮键相互连接，形成了一个复杂的分子结构。
咪唑并[1,2-a]吡啶-6-基团是赛沃替尼的一个关键部分，它具有强烈的芳香性，为分子提供了稳定性和反应活性。
1-甲基-1H-吡唑-4-基团则是一个具有生物活性的基团，它可以通过与生物体内的受体结合来发挥药效。
1H-[1,2,3]三唑并[4,5-b]吡嗪基团是赛沃替尼分子的核心部分，它具有高度的平面性和共轭性，能够稳定地存在于分子中，并且与咪唑并[1,2-a]吡啶-6-基团和1-甲基-1H-吡唑-4-基团相互作用，共同构成了赛沃替尼的分子骨架。
总的来说，赛沃替尼的化学结构具有高度的复杂性和独特性，这种结构使得它能够在生物体内发挥强大的药理作用，成为一种有效的药物分子。
溴吡斯的明引起重症肌无力患者心肌梗死的1例报告并文献复习
J Apoplexy and Nervous Diseases, Nov. 2023, Vol 40，No. 11溴吡斯的明引起重症肌无力患者心肌梗死的1例报告并文献复习周丽枝， 胡云， 周礼鑫， 童理， 杨剑文摘要： 重症肌无力是一种自身免疫性疾病，通常由针对神经肌肉接头处的乙酰胆碱受体的抗体介导，其常见的治疗有胆碱酯酶抑制剂，例如溴吡斯的明。
该药物在治疗过程中出现心血管事件较少见，但在临床中早期识别病情变化并警惕重症肌无力患者可能出现的心血管事件非常重要。
因此，我们报道重症肌无力老年女性患者继发于抗胆碱酯酶治疗导致急性心肌梗死并发心源性猝死的病例，并基于此病例对发生心血管不良事件的可能原因进行讨论。
关键词： 重症肌无力； 急性心肌梗死； 溴吡斯的明； 胆碱酯酶抑制剂中图分类号：R741 文献标识码：APyridostigmine bromide causes myocardial infarction in myasthenia gravis ： a case report and literature reviewZHOU Lizhi ，HU Yun ，ZHOU Lixin ， et al.（The First Affiliated Hospital of Hunan Normal University ， Changsha 410005， China ）Abstract ： Myasthenia gravis is an autoimmune disease ，which is usually mediated by antibodies to acetylcholine re⁃ceptors at the neuromuscular junction. It is commonly treated with cholinesterase inhibitors such as pyridostigmine bro⁃mide. Although cardiovascular events with the drug are rare ，it is very important to early recognize disease changes and be alert to potential cardiovascular events in patients with myasthenia gravis. Therefore ， we report a case of an elderly female patient with myasthenia gravis developing acute myocardial infarction and then sudden cardiac death following anticholines⁃terase therapy ， and discuss the possible causes of adverse cardiovascular events based on this case.Key words ： Myasthenia gravis ； Myocardial infarction ； Pyridostigmine bromide ； Cholinesterase inhibitor重症肌无力（myasthenia ，MG ）是一种自身免疫性疾病，通常由针对神经肌肉接头处的乙酰胆碱受体的抗体介导，其特征临床表现为骨骼肌无力和易疲劳［1］。